HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.108.053785v1 49/12/1944    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Komar, G. Articles by Minn, H. Search for Related Content PubMed PubMed Citation Articles by Komar, G. Articles by Minn, H.

¹⁸F-EF5: A New PET Tracer for Imaging Hypoxia in Head and Neck Cancer

¹ Turku PET Centre, Turku, Finland; ² Department of Oncology and Radiotherapy, University of Turku, Turku, Finland; and ³ Department of Radiation Oncology, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Correspondence: For correspondence or reprints contact: Gaber Komar, Turku PET Centre, P.O. Box 52, FIN-20521, Turku, Finland. E-mail: gaber.komar{at}tyks.fi

The aim of this study was to evaluate 2-(2-nitro-¹H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)-acetamide (EF5) labeled with ¹⁸F-fluorine to image hypoxia in patients with squamous cell carcinoma of the head and neck (HNSCC). Methods: Fifteen patients with HNSCC were studied. Measurement of tumor blood flow was followed by an ¹⁸F-EF5 PET/CT scan. On a separate day, ¹⁸F-FDG PET/CT was performed to determine the metabolically active tumor volume. In 6 patients, dynamic ¹⁸F-EF5 images of the head and neck area were acquired, followed by static images acquired at 1, 2, and 3 h after injection. In the remaining 9 patients, only static images were obtained. ¹⁸F-EF5 uptake in tumors was compared with that in neck muscle, and the ¹⁸F-EF5 findings were correlated with the ¹⁸F-FDG PET/CT studies. Results: A total of 13 primary tumors and 5 lymph node metastases were evaluated for their uptake of ¹⁸F-EF5. The median tumor-to-muscle ¹⁸F-EF5 uptake ratio (T/M) increased over time and was 1.38 (range, 1.1–3.2) 3 h after tracer injection. The median blood flow in tumors was 36.7 mL/100 g/min (range, 23.3–78.6 mL/100 g/min). Voxel-by-voxel analysis of coregistered blood flow and ¹⁸F-EF5 images revealed a distinct pattern, resulting in a T/M of 1.5 at 3 h to be chosen as a cutoff for clinically significant hypoxia. Fourteen of 18 tumors (78%) had subvolumes within the metabolically active tumor volumes with T/M greater than or equal to 1.5. Conclusion: On the basis of these data, the potential of ¹⁸F-EF5 to detect hypoxia in HNSCC is encouraging. Further development of ¹⁸F-EF5 for eventual targeting of antihypoxia therapies is warranted.

Key Words: head and neck cancer • hypoxia • ¹⁸F-EF5 • squamous cell carcinoma

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]  

This article has been cited by other articles:

				G. Komar, S. Kauhanen, K. Liukko, M. Seppanen, S. Kajander, J. Ovaska, P. Nuutila, and H. Minn Decreased Blood Flow with Increased Metabolic Activity: A Novel Sign of Pancreatic Tumor Aggressiveness Clin. Cancer Res., September 1, 2009; 15(17): 5511 - 5517. [Abstract] [Full Text] [PDF]